Atara Biotherap (ATRA)

$1.51 0.03 (2.03%)

9:39 EDT ATRA Stock Quote Delayed 30 Minutes

3 Doomed Biotech Stocks Destined for Disaster

By Alex Sirois, InvestorPlace Contributor Jul 17, 2023

Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures.

3 Stocks to Buy That Could Be the Next Biotech Breakthrough

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Volume:

Previous Close -

Market Cap 152.66M

PE Ratio -0.51

EPS -2.95

Volume (Avg. Vol.) 97,365

Day's Range $1.48 - $1.51

52-Week Range $1.25 - $5.64

Dividend & Yield N/A (N/A)

ATRA Stock Predictions, Articles, and Atara Biotherap News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Dec 14, 2021

Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday!

7 Stocks That Could Double by Summer

By Tom Taulli, InvestorPlace Contributor Apr 5, 2021

These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer.

7 Disruptive Biotech Stocks to Buy for 2025

By Harriet Lefton, Writer, TipRanks Apr 27, 2020

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

5 Biotech Stocks to Sell Amid the Latest Slaughter

By Anthony Mirhaydari, InvestorPlace Market Strategist Feb 28, 2018

These five biotech stocks are being hit particularly hard right now. Here's what investors should know about each of these stocks to sell.

Atara sees filing for FDA approval of Tab-cel in Q2 2024 (ATRA)

From Seeking Alpha Sep 19, 2023

Atara Biotherapeutics (ATRA) said that after meeting with the FDA, it now plans to submit the Biologics License Application for Tab-cel in Q2 2024. Read more here.

Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.30, revenue of $0.22M misses by $39.45M (NASDAQ:ATRA)

From Seeking Alpha Feb 8, 2023

Atara Biotherapeutics press release (NASDAQ:ATRA): Q4 GAAP EPS of -$0.72 misses by $0.30.Revenue of $0.22M (-97.1% Y/Y) misses by $39.45M.

3 Under-the-Radar Biotech Stocks to Buy in 2022

From The Motley Fool Dec 24, 2022

The attraction of all three biotech stocks is their potential.

Mizuho Securities Sticks to Its Buy Rating for Atara Biotherapeutics (ATRA)

From TipRanks Nov 22, 2022

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report), with a price target o...

Mizuho Securities Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)

From TipRanks Nov 9, 2022

In a report released yesterday, Salim Syed from Mizuho Securities maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report), with a price targ...

Analysts Are Bullish on Top Healthcare Stocks: First Wave Bio (FWBI), Atara Biotherapeutics (ATRA)

From TipRanks Oct 31, 2022

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on First Wave Bio (

Atara Biotherap (ATRA)

3 Doomed Biotech Stocks Destined for Disaster

3 Stocks to Buy That Could Be the Next Biotech Breakthrough

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Atara Biotherap (ATRA)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ATRA Stock Predictions, Articles, and Atara Biotherap News

Subscriber Sign in